Clinical Study
Taking rivaroxaban is a risk factor for acute kidney disease and disorders in patients with coronary heart disease or non-valvular atrial fibrillation
Li Wen, Dong Xingtong, Jia Qiang, Fu Wenjing, Lin Na, Liu Hua, Zhang Aihua
Published 2020-10-15
Cite as Chin J Nephrol, 2020, 36(10): 744-749. DOI: 10.3760/cma.j.cn441217-20191101-00132
Abstract
ObjectiveTo observe the risk of acute kidney disease and disorders (AKD) in patients with coronary heart disease or non-valvular atrial fibrillation who were taking rivaroxaban for the first time in our hospital.
MethodsA retrospective case-control analysis was performed using the hospital database to screen for patients with coronary heart disease or non-valvular atrial fibrillation who were taking rivaroxaban for the first time for more than 3 months during January 1, 2018 to June 30, 2019. A total of 279 patients with serum creatinine reviewed within 3 months were as the rivaroxaban group, and 317 patients with coronary heart disease or non-valvular atrial fibrillation who did not take rivaroxaban during the same period in our hospital were selected as the control group. The general condition and the incidence of AKD were compared between the two groups, and the influencing factors of AKD were analyzed by logistic regression analysis.
ResultsThe prothrombin time and international normalized ratio were higher in the rivaroxaban group than those in the control group (both P<0.01). There was no significant difference in age, gender, serum creatinine and urea level between the two groups. The incidence of AKD in the rivaroxaban group was 4.30%(12/279), and the incidence of AKD in the control group was 1.26%(4/317). The relative risk (RR) of the two groups of patients was 3.409. Logistic regression analysis showed that older age (≥75 years old, OR=1.166, 95%CI 1.012-1.343, P=0.033) and diabetes (OR=34.261, 95%CI 1.639-716.326, P=0.023) were risk factors for AKD in patients taking rivaroxaban. Rivaroxaban was a risk factor for AKD in patients with coronary heart disease or non-valvular atrial fibrillation (OR=3.500, 95%CI 1.115-10.988, P=0.032).
ConclusionsThe incidence of AKD in patients taking rivaroxaban for the first time due to coronary heart disease or non-valvular atrial fibrillation was 4.30%. Taking rivaroxaban is a risk factor for AKD in patients with coronary heart disease or non-valvular atrial fibrillation. Older age and diabetes are the risk factors for AKD in the rivaroxaban group.
Key words:
Coronary disease; Atrial fibrillation; Risk factors; Rivaroxaban; Acute kidney disease and disorders
Contributor Information
Li Wen
Department of Nephrology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Dong Xingtong
Department of Nephrology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Jia Qiang
Department of Nephrology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Fu Wenjing
Department of Nephrology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Lin Na
Department of Nephrology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Liu Hua
Department of Nephrology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Zhang Aihua
Department of Nephrology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
